Viriom
Biopharmaceutical company developing antiviral and oncology therapies with a global-access focus. Operates a drug development platform spanning discovery, preclinical studies, clinical trials (including long-acting injectable and extended‑interval oral formulations), regulatory filings and regional commercialization partnerships to advance affordable treatments for viral and malignant diseases.
Industries
Nr. of Employees
large (251-1000)
Patents
Substituted 3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, pharmaceutical composition, method for the production and use thereof
US-12091423-B2
View Details
Substituted 3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, pharmaceutical composition, method for the production and use thereof
US-12091423-B2
View DetailsProducts
Elsulfavirine (Elpida) — oral NNRTI for HIV-1
Oral NNRTI prodrug developed for HIV-1 treatment; evaluated in clinical studies for daily dosing and reformulated for less‑frequent oral regimens and prophylaxis.
Agape FDC — fixed-dose combination for HIV-1
Fixed-dose combination tablet combining elsulfavirine with nucleoside reverse transcriptase inhibitors intended as a complete regimen.
Depulfavirine — monthly nanospheric injectable for HIV-1
Nanosphere-formulated injectable designed for once-monthly or less-frequent use as part of combination therapy.
VM3500 — long-acting injectable integrase inhibitor (preclinical)
Long-acting injectable formulation of a novel integrase strand transfer inhibitor in preclinical development for combination HIV therapy.
Antiviral combinations for SARS-CoV-2 and influenza (clinical and preclinical assets)
Development of high‑potency antiviral combinations and prophylactic treatments for SARS-CoV-2 and seasonal/pandemic influenza; includes favipiravir-containing regimens and investigational influenza inhibitors advanced to human trials.
Quisinostat — oral HDAC inhibitor for solid tumors (Phase II)
Oral selective pan‑HDAC inhibitor in Phase II development for ovarian and other solid tumors, evaluated in combination with standard chemotherapies and immunomodulators.
Elsulfavirine (Elpida) — oral NNRTI for HIV-1
Oral NNRTI prodrug developed for HIV-1 treatment; evaluated in clinical studies for daily dosing and reformulated for less‑frequent oral regimens and prophylaxis.
Agape FDC — fixed-dose combination for HIV-1
Fixed-dose combination tablet combining elsulfavirine with nucleoside reverse transcriptase inhibitors intended as a complete regimen.
Depulfavirine — monthly nanospheric injectable for HIV-1
Nanosphere-formulated injectable designed for once-monthly or less-frequent use as part of combination therapy.
VM3500 — long-acting injectable integrase inhibitor (preclinical)
Long-acting injectable formulation of a novel integrase strand transfer inhibitor in preclinical development for combination HIV therapy.
Antiviral combinations for SARS-CoV-2 and influenza (clinical and preclinical assets)
Development of high‑potency antiviral combinations and prophylactic treatments for SARS-CoV-2 and seasonal/pandemic influenza; includes favipiravir-containing regimens and investigational influenza inhibitors advanced to human trials.
Quisinostat — oral HDAC inhibitor for solid tumors (Phase II)
Oral selective pan‑HDAC inhibitor in Phase II development for ovarian and other solid tumors, evaluated in combination with standard chemotherapies and immunomodulators.
Services
Negotiation and execution of regional licensing, co-development and financing agreements to support registration and commercialization.
Negotiation and execution of regional licensing, co-development and financing agreements to support registration and commercialization.
Expertise Areas
- Clinical trial management
- Antiviral drug discovery and development
- Long-acting formulation development
- Fixed-dose combination development
Key Technologies
- Long-acting injectable nanoformulations
- Extended-interval oral formulations (weekly dosing)
- Prodrug design
- Fixed-dose combination formulation
News & Updates
Announcement of successful completion and positive results of a Phase I clinical trial for a novel influenza virus replication inhibitor (AV5124).
Comparative assessment of favipiravir, molnupiravir and nirmatrelvir/ritonavir (Paxlovid) risk/benefit profiles for COVID-19 treatment.
Report on accelerated registration of an oral antiviral (Avifavir) in Indonesia based on GCP Phase II–III trial data involving 460 patients.
Announcement of initiation of a Phase 2a study to investigate efficacy of an intramuscular long-acting injectable nanoformulation of VM1500A in HIV-infected patients.
Collection of conference posters and study reports covering PK, safety and preclinical development for elsulfavirine/VM1500A and other programs.
Market authorization and launches of elsulfavirine-containing regimens in Russia and EurAsEC countries; licensing agreements and first launches in multiple countries.
Announcement of successful completion and positive results of a Phase I clinical trial for a novel influenza virus replication inhibitor (AV5124).
Comparative assessment of favipiravir, molnupiravir and nirmatrelvir/ritonavir (Paxlovid) risk/benefit profiles for COVID-19 treatment.
Report on accelerated registration of an oral antiviral (Avifavir) in Indonesia based on GCP Phase II–III trial data involving 460 patients.
Announcement of initiation of a Phase 2a study to investigate efficacy of an intramuscular long-acting injectable nanoformulation of VM1500A in HIV-infected patients.
Collection of conference posters and study reports covering PK, safety and preclinical development for elsulfavirine/VM1500A and other programs.
Market authorization and launches of elsulfavirine-containing regimens in Russia and EurAsEC countries; licensing agreements and first launches in multiple countries.